Results of clinical evaluation of gefitinib therapeutic activity and toxicity in early access programme of NSCLC treatment in Czech Republic
2009
Abstract
Authors evaluated therapeutic responses, time to progression and overal survival of NSCLC patients treated by gefitinib in Czech patients. Comparable efficacy and tolerance of therapy was found if compared with results of other authors.